MARKET

CDAK

CDAK

Codiak BioSciences, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.40
-0.10
-1.05%
Closed 16:00 10/26 EDT
OPEN
9.50
PREV CLOSE
9.50
HIGH
9.65
LOW
9.30
VOLUME
58.35K
TURNOVER
--
52 WEEK HIGH
14.40
52 WEEK LOW
9.05
MARKET CAP
174.79M
P/E (TTM)
-11.3568
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Foghorn Therapeutics Is Latest Biotech to Go Public
The company sold 7.5 million shares at $16 each, the midpoint of its expected $15 to $17 price range.
Barrons.com · 3d ago
Foghorn Therapeutics Is Latest Biotech to Go Public
The company sold 7.5 million shares at $16 each, the midpoint of its expected $15 to $17 price range.
Barrons.com · 3d ago
The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 21)
Benzinga · 4d ago
The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20)
Benzinga · 5d ago
U.S. IPO Weekly Recap: Solar Technology Shines In A 9-IPO Week
Nine IPOs and five SPACs went public this past week, and one IPO postponed.New filing activity continued to pump the brakes as we near the election, with just one new IPO filing.SPAC activity continued unabated however as nine submitted initial filings.
Seekingalpha · 10/18 18:51
The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 15)
Benzinga · 10/16 11:15
Codiak Bio prices IPO at $15
Codiak BioSciences (CDAK) has priced its IPO of 5.5M common shares at $15.00/share, for gross proceeds of ~$82.5M.Underwriters' over-allotment is an additional 825K shares. Trading kicks off October 14. Closing
Seekingalpha · 10/14 09:07
U.S. IPO Week Ahead: Healthcare, Solar Panels, And Chinese Retail In A 9 IPO Week
Five biotechs, two medical device makers, a solar panel mounting manufacturer, and a Chinese retailer are scheduled to raise $2.0 billion in the week ahead.Several companies could join the IPO calendar early in the week, including McAfee and Datto Holding.Street research is expected for 15 companies.The lock-up for Renalytix AI will be expiring on Thursday, 10/15.
Seekingalpha · 10/11 20:55
More
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CDAK. Analyze the recent business situations of Codiak BioSciences, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.51%
Pharmaceuticals & Medical Research
-0.94%
Key Executives
Chairman/Director
Steven Gillis
President/Chief Executive Officer/Director
Douglas Williams
Chief Financial Officer/Primary Contact
Linda Bain
Executive Officer
Ariel Jasie
Executive Officer
Jan Lotvall
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CDAK
Codiak BioSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of exosome-based therapeutics. The Company has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. It utilizes the engEx Platform to generate a pipeline of engineered exosomes (engEx) exosomes, focused at treating a range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. The Company's product candidates, exoSTING and exoIL-12, are developed to address solid tumors. The Company's program, exoSTING, is an exosome therapeutic candidate engineered with its engEx Platform to carry stimulator of interferon genes (STING) agonist inside the lumen of the exosome while expressing prostaglandin F2 receptor negative regulator (PTGFRN).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Codiak BioSciences Inc stock information, including NASDAQ:CDAK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDAK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDAK stock methods without spending real money on the virtual paper trading platform.